Frontline immunotherapy for NSCLC — the tale of the tail
Nature Reviews Clinical Oncology, Published online: 06 January 2020; doi:10.1038/s41571-019-0317-yThe CHECKMATE-227 trial of nivolumab and ipilimumab presents a potential new frontline chemotherapy-sparing treatment option for patients with PD-L1-positive non-small-cell lung cancer and perhaps, in the future, also for those with PD-L1-negative disease. Indeed, the true predictive value of PD-L1 as well as tumour mutational burden remains to be determined, as neither biomarker segregates clearly with responsiveness.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Anne C. Chiang Roy S. Herbst Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Yervoy